The Maria Sklodowska-Curie National Research Institute of Oncology, Branch in Gliwice
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rutkowski, Tomasz
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Recruiting
3
864
Europe, Canada, Japan, US, RoW
Dostarlimab, Placebo
GlaxoSmithKline
Neoplasms, Head and Neck
05/28
07/29
XRAY VISION, NCT05386550 / 2022-001144-18: Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants

Terminated
3
166
Europe, Canada, Japan, US, RoW
Xevinapant (Debio 1143), IMRT, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Head and Neck Cancer
08/24
08/24
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
NIVONASO-21, NCT04875611: Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment

Not yet recruiting
2
32
Europe
Opdivo, Nivolumab
Maria Sklodowska-Curie Institute - Oncology Center, KCRI
Nasopharyngeal Cancer
09/23
12/25
NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
KEYNOTE-E72, NCT06016920: Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

Recruiting
1/2
51
Europe, RoW
VB10.16, Pembrolizumab, KEYTRUDA®
Nykode Therapeutics ASA, Merck Sharp & Dohme LLC
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
09/27
01/28
iCHRTL, NCT05992610: Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy

Recruiting
N/A
40
Europe
Chemotherapy (carboplatin+paclitaxel) with concomitant low dose ionizing radiotherapy
Maria Sklodowska-Curie National Research Institute of Oncology, Medical Research Agency, Poland
Squamous Cell Carcinoma of Oral Cavity, Pharynx Carcinoma, Larynx Carcinoma, Paranasal Sinus Carcinoma
03/25
03/26
Składowski, Krzysztof
iCHRTL, NCT05992610: Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy

Recruiting
N/A
40
Europe
Chemotherapy (carboplatin+paclitaxel) with concomitant low dose ionizing radiotherapy
Maria Sklodowska-Curie National Research Institute of Oncology, Medical Research Agency, Poland
Squamous Cell Carcinoma of Oral Cavity, Pharynx Carcinoma, Larynx Carcinoma, Paranasal Sinus Carcinoma
03/25
03/26

Download Options